
The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition
Keywords: Park8; Dardarin; Pharmacodynamics; Pharmacokinetics; Small-molecule inhibitor; LRRK2; Leucine-rich repeat kinase 2; PD; Parkinson disease; ATP; adenosine-tri phosphate; DTT; dithiothreitol; HSC70; Heat-shock cognate 70; Rab; Ras gene from rat brain, or Ra